|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2009-2-2
|
|
pubmed:abstractText |
Neutralising antibodies (NAb) to interferon beta (IFN beta) are associated with a reduced bioactivity and efficacy of IFN beta in multiple sclerosis (MS). Unclear is how to apply IFN beta bioactivity measurements (quantification of Myxovirus resistance protein A (MxA) mRNA) in clinical practice.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1352-4585
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
212-8
|
|
pubmed:meshHeading |
pubmed-meshheading:18805837-Adult,
pubmed-meshheading:18805837-Antibodies,
pubmed-meshheading:18805837-Drug Monitoring,
pubmed-meshheading:18805837-Feasibility Studies,
pubmed-meshheading:18805837-Female,
pubmed-meshheading:18805837-GTP-Binding Proteins,
pubmed-meshheading:18805837-Gene Expression Regulation, Viral,
pubmed-meshheading:18805837-Humans,
pubmed-meshheading:18805837-Immunoassay,
pubmed-meshheading:18805837-Immunologic Factors,
pubmed-meshheading:18805837-Interferon-beta,
pubmed-meshheading:18805837-Male,
pubmed-meshheading:18805837-Middle Aged,
pubmed-meshheading:18805837-Multiple Sclerosis, Relapsing-Remitting,
pubmed-meshheading:18805837-Neutralization Tests,
pubmed-meshheading:18805837-RNA, Messenger,
pubmed-meshheading:18805837-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
|
|
pubmed:affiliation |
Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands. laura.vandervoort@vumc.nl
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
